Enhancement of the adaptive signature design for learning and confirming in a single pivotal trial.

about

Enhancement of the adaptive signature design for learning and confirming in a single pivotal trial.

Item

http://www.wikidata.org/entity/Q48187708

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@en

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@nl

type

Item

label

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@en

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@nl

prefLabel

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@en

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@nl

P1476

Enhancement of the adaptive si ...... ing in a single pivotal trial.

@en

P2860

Random Forests

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Pembrolizumab for the treatment of non-small-cell lung cancer

Optimally splitting cases for training and testing high dimensional classifiers

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.

Integrating predictive biomarkers and classifiers into oncology clinical development programmes.

A regression tree approach to identifying subgroups with differential treatment effects

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.

An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.

P304

312-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PST.1811

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gu Mi

P577

2017-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28474369

http://www.w3.org/2001/XMLSchema#string